Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma

Table 1 Peripheral blood T lymphocyte subset analysis

Patient	Pre-treatment (%)	After pulse radiotherapy and 2 cycles of atezolizumab (%)
Patient A
PD-1+ T cells/T cells	2.13	0.80
PD-1+ helper T cells/helper T cells	2.31	0.43
PD-1+ cytotoxic T cells/cytotoxic T cells	1.67	0.90
CD8+ terminally differentiated effector T cells/cytotoxic T cells	39.29	42.71
CD8+ effector memory T cells/cytotoxic T cells	34.47	50.57
Patient B
PD-1+ T cells/T cells	1.16	0.40
PD-1+ helper T cells/helper T cells	0.97	0.37
PD-1+ cytotoxic T cells/cytotoxic T cells	1.55	0.33
CD8+ terminally differentiated effector T cells/cytotoxic T cells	55.52	38.24
CD8+ effector memory T cells/cytotoxic T cells	22.27	21.59
Patient C
PD-1+ T cells/T cells	0.04	0.22
PD-1+ helper T cells/helper T cells	0.03	0.19
PD-1+ cytotoxic T cells/cytotoxic T cells	0.05	0.15
CD8+ terminally differentiated effector T cells/cytotoxic T cells	40.11	55.15
CD8+ effector memory T cells/cytotoxic T cells	31.94	25.37
Patient D
PD-1+ T cells/T cells	1.24	4.92
PD-1+ helper T cells/helper T cells	1.29	9.08
PD-1+ cytotoxic T cells/cytotoxic T cells	1.29	2.94
CD8+ terminally differentiated effector T cells/cytotoxic T cells	13.09	17.10
CD8+ effector memory T cells/cytotoxic T cells	32.09	70.39

PD-1: Programmed death 1.